quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:04:02·65d
SECFiling
IDEAYA Biosciences Inc. logo

IDEAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

IDYA· IDEAYA Biosciences Inc.
Health Care
Original source

Companies

  • IDYA
    IDEAYA Biosciences Inc.
    Health Care

Recent analyst ratings

  • Jan 7UpdateUBS$50.00
  • Nov 24UpdateTruist-
  • Sep 18UpdateGuggenheim$50.00
  • Sep 4UpdateBarclays$40.00
  • Sep 4UpdateCitizens JMP$41.00
  • Jul 22UpdateTD Cowen-

Related

  • PR2d
    IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
  • SEC10d
    SEC Form 8-K filed by IDEAYA Biosciences Inc.
  • PR10d
    IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
  • PR13d
    IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
  • SEC14d
    SEC Form 8-K filed by IDEAYA Biosciences Inc.
  • PR17d
    IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
  • PR24d
    IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022